ATE357226T1 - (d)-methadon, ein nicht-opioides schmerzmittel - Google Patents

(d)-methadon, ein nicht-opioides schmerzmittel

Info

Publication number
ATE357226T1
ATE357226T1 AT98904609T AT98904609T ATE357226T1 AT E357226 T1 ATE357226 T1 AT E357226T1 AT 98904609 T AT98904609 T AT 98904609T AT 98904609 T AT98904609 T AT 98904609T AT E357226 T1 ATE357226 T1 AT E357226T1
Authority
AT
Austria
Prior art keywords
alpha
subject
methadone
pain relief
normethadol
Prior art date
Application number
AT98904609T
Other languages
English (en)
Inventor
Charles E Inturrisi
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of ATE357226T1 publication Critical patent/ATE357226T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98904609T 1997-01-22 1998-01-21 (d)-methadon, ein nicht-opioides schmerzmittel ATE357226T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3530897P 1997-01-22 1997-01-22

Publications (1)

Publication Number Publication Date
ATE357226T1 true ATE357226T1 (de) 2007-04-15

Family

ID=21881853

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904609T ATE357226T1 (de) 1997-01-22 1998-01-21 (d)-methadon, ein nicht-opioides schmerzmittel

Country Status (12)

Country Link
US (1) US6008258A (de)
EP (1) EP1003494B1 (de)
JP (2) JP4514241B2 (de)
AT (1) ATE357226T1 (de)
AU (1) AU6244898A (de)
CA (1) CA2278422C (de)
DE (1) DE69837387T2 (de)
DK (1) DK1003494T3 (de)
ES (1) ES2283049T3 (de)
MA (1) MA24794A1 (de)
PT (1) PT1003494E (de)
WO (1) WO1998031358A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197651A1 (en) * 1998-03-09 2007-08-23 Tufts University Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US20060167114A1 (en) * 1998-03-09 2006-07-27 Louis Shuster Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
CN1309562A (zh) * 1998-07-16 2001-08-22 纪念斯隆-凯特林癌症中心 包括一种阿片样物质镇痛剂和一种nmda拮抗剂的局部给药组合物
US6897242B1 (en) * 1999-02-24 2005-05-24 Judson J. Somerville Non-racemic mixtures of d- and l- methadone and method of treating pain
WO2001076522A1 (en) * 2000-04-07 2001-10-18 Ultramed International, Inc. Maintaining abstinence after detoxification from opiate addiction
JP2004512260A (ja) 2000-04-28 2004-04-22 メモリアル　スローン−ケッタリング　キャンサー　センター 局所麻酔／オピオイド製剤およびその使用方法
US7820688B2 (en) 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
EP1476155A4 (de) * 2002-01-23 2009-10-28 Univ California Verfahren und zusammensetzungen zur verringerung der entstehung von arzneimitteltoleranz und/oder physischer abhängigkeit
US20060058331A1 (en) * 2002-05-13 2006-03-16 Bradley Galer Abuse resistant opioid dosage form
EP1545461A4 (de) * 2002-09-09 2011-06-22 Endo Pharmaceuticals Inc Analgetische zusammensetzung mit kombinierter sofortiger freisetzung und verlängerter freisetzung
US20040180915A1 (en) * 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20100010096A1 (en) * 2006-10-27 2010-01-14 John Charin Somberg Methadone chiral isolate as an improved pharmaceutical
WO2008073381A2 (en) * 2006-12-11 2008-06-19 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
US9468611B2 (en) 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
KR20190124722A (ko) * 2017-01-31 2019-11-05 파올로 엘. 만프레디 신경계 장애의 치료에서 사용하기 위한 ｄ-메타돈 및 이의 유도체
WO2018183320A1 (en) * 2017-03-31 2018-10-04 Depco, Inc. Therapeutic putty having analgesics and/or counterirritants
CN113646044A (zh) * 2019-01-30 2021-11-12 帕多瓦大学 用于预防和治疗疾病和病症的结构修饰的阿片类药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895056A (en) * 1972-12-26 1975-07-15 Lilly Co Eli Alpha-d1-4-acetoxy-1-methyl-3,3-diphenylhexylamine and salts
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5352683A (en) * 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain

Also Published As

Publication number Publication date
MA24794A1 (fr) 1999-12-31
PT1003494E (pt) 2007-06-06
DE69837387T2 (de) 2007-12-13
ES2283049T3 (es) 2007-10-16
EP1003494A1 (de) 2000-05-31
JP2010013477A (ja) 2010-01-21
CA2278422C (en) 2007-11-13
DK1003494T3 (da) 2007-07-16
CA2278422A1 (en) 1998-07-23
JP4514241B2 (ja) 2010-07-28
JP2001508797A (ja) 2001-07-03
EP1003494B1 (de) 2007-03-21
US6008258A (en) 1999-12-28
EP1003494A4 (de) 2002-10-16
DE69837387D1 (de) 2007-05-03
AU6244898A (en) 1998-08-07
WO1998031358A1 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
DE69837387D1 (de) (d)-METHADON, EIN NICHT-OPIOIDES SCHMERZMITTEL
CA2146973A1 (en) Uses of tgf-.beta. receptor fragment as a therapeutic agent
IL128003A (en) MULTISPECIFIC BINDING MOLECULES COMPRISING A BINDING DETERMINANT WHICH BINDS AN FCalpha RECEPTOR
FI965203A7 (fi) Morfiinia, polypyrrolidonia ja polyalkyleenioksidia sisältävä koostumus
CA2271857A1 (en) Method for treating symptoms of diabetes
IT8822374A0 (it) Procedimento per distribuire, su richiesta, copie di documenti immagazzinati in forma leggibile da macchina.
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
BG101392A (en) Method of treating diabetes mellitus using kgf
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
PT1033990E (pt) 21-hidroxi-6,19-oxidoprogesterona (21oh-6op) e a sua utilizacao como medicamento para tratar o excesso de glucocorticoides
EP1632248B8 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DK0810883T3 (da) Konjugat indeholdende DTPA og albumin til individuel dosering af lægemidler
NO996287D0 (no) Chalkoner med antiproliferativ aktivitet
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
FI963638A7 (fi) Menetelmiä HIV-1-injektion diagnosoimiseksi ja hoitamiseksi
CA2299400A1 (en) Method for treating disease-related or drug-induced dyskinesias
WO1998020835A3 (en) Method of treating hyperlipidemia in humans
WO2000051632A3 (de) Kupferagonist, der an die amyloid precursorprotein (app) bindet und/oder eine hemmende wirkung auf die amyloid-a beta-peptids ausübt
HUP0000110A3 (en) Pharmaceutical compositions comprising azacyclic, azabicyclic or tetrahydro-pyridine-derivatives suitable for treating pain
ZA986939B (en) An apparatus for the manufacture of individual holograms to make documents secure.
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
EP1007050A4 (de) Verfahren zur behandlung von drogenmissbrauch
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
SE9404438D0 (sv) New process
BR9612549A (pt) Método para tratamento de agressão excessiva

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties